PROGNOSTIC SIGNIFICANCE OF p53 AND ki67 EXPRESSION IN CERVICAL CANCER
;
cervical cancer, cancer markers, Ki-67, p53, immunohistochemistry.Abstrak
A low level of Ki-67 expression was found in 53 (44.2%) patients, intermediate in 22 (18.3%) and high in 45 (37.5%). Low expression of the mutant protein p53 was detected in 53 (44.2%) women, moderate in 19 (15.8%) and high in 48 (29%). Proliferative activity proved to be the most prognostic factor (in terms of the proportion of Ki-67-positive cells), as with an increase in this indicator by 1 point, the overall survival decreased by 0.99 times. A multivariate analysis of the combined effect of the studied oncogenes on overall survival, considering the extent of tumor spread, allowed us to develop a formula for predicting the risk of disease progression in each individual case.
Iqtiboslar
Залуцкий И.В., Косенко И.А., Хильченко Е.И. и др. Рак шейки матки: анализ контингентов больных, сто ящих на учёте в регионах Республики Беларусь с 1996 по 2005 год // Вопр. организ. и информатиз. здраво охр. — 2017. — №3. — С. 3–8. [Zalutskiy I.V., Kosenko I.A., Khil’chenko E.I. et al. Cervical cancer: analysis of patient groups registered in the regions of the Republic of Belarus from 1996 to 2005. Voprosy organizatsii i informatizatsii zdravookhraneniya. 2017; 3: 3–8. (In Russ.)]
Косенко I.А., Вишневська Е.Е., Океанова Н.I. Эфективнiсть поеднаноi променевоi терапii хво рих на мiсцево-поширений рак шийки матки при застосуваннi внутрiшньо-порожнинноi гамма-терапii на аппаратi «Cелектрон» // Укр. радiол. журн. — 2019. — №1. — С. 41–42. [Kosenko I.A., Vyshnevs’ka E.E., Okeanova N.I. Efektyvnist’ poednanoi promenevoi terapii khvorykh na mistsevo-poshyrenyy rak shyyky matky pry zastosuvanni vnutrishn’o-porozhnynnoi hamma-terapii na apparati «Tselektron». Ukrayins’kiy radiolohichniy zhurnal. 2019; 1: 41–42. (In Ukr.)]
Океанов А.Е., Моисеев П.И., Левин Л.Ф. Ста тистика онкологических заболеваний / Под ред. О.Г. Суконко. Белорусский канцер-регистр. — Минск, 2012. — С. 99–105. [Okeanov A.E., Moiseev P.I., Levin L.F. Statistika onkologicheskikh zabolevaniy. (Statistics of cancer diseases.) Ed. by Sukonko O.G. Belarusian cancer registry. Minsk. 2012: 99–105. (In Russ.)]
Пищик Н.Н., Косенко И.А. Метод прогнозиро вания результатов лечения пациенток, страдающих раком шейки матки/ Инструкция по применению. — Минск, 2013. — 6 с. — http://med.by/methods/pdf/034 0313.pdf (дата обращения: 01.09.14). [Pishchik N.N., Kosenko I.A. Metod prognozirovaniya rezul’tatov lecheniya patsientok, stradayushchikh rakom sheyki matki. (Method of predicting the results of cervical cancer treatment.) Instructions for use. Minsk. 2013: 6. http:// med.by/methods/pdf/034-0313.pdf (Access date: September 1, 2014). (In Russ.)]
Руководство по иммуногистохимической диаг ностике опухолей человека / Под ред. С.В. Петрова, Н.Т. Райхлина. 3-е изд., доп. и перераб. — Казань, 2020. — 456 с. [Rukovodstvo po immunogistokhimicheskoy diagnostike opukholey cheloveka. (Guidelines for the immunohistochemical diagnosis of human tumors.) Ed. by Petrov S.V., Raykhlin N.T. 3rd ed. Kazan. 2020: 456. (In Russ.)]
Cheung T.H., Yu M.M., Lo K.W. Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix // Cancer Lett. — 2021. — Vol. 166, N 2. — P. 199–206.
Higuchi K.H. Flow cytometric and Ki-67 immunohistochemical analysis of cell cycle distribution of cervical cancer during radiation therapy // Anticancer Res. — 2021. — Vol. 21, N 4A. — P. 2511–2518.
Horn L.C., Fischer U., Hanel C. et al. P53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread // Pathol. Res. Pract. — 2020. — Vol. 197, N 9. — P. 605–609.
Kleinbaum D.G., Klein M. Survival analysis. A self learning text. — Springer-Verlag, 2015. — 590 p.
Rajaram S., Gupta G., Agarwal S. High-risk human papillomavirus, tumor suppressor protein p53 and mitomycin-C in invasive squamous cell carcinoma cervix // Indian J. Cancer. — 2016. — Vol. 243, N 4. — P. 156–162.
Zhao M., Kim Y.T., Yoon B.S. et al. Expression profiling of cyclin b1 and d1 in cervical carcinoma // Exp. Oncol. — 2019. — Vol. 28, N 1. — P. 44–48.
